Severe infections of Panton-Valentine leukocidin positive Staphylococcus aureus in children.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
Sep 2019
Historique:
entrez: 1 10 2019
pubmed: 1 10 2019
medline: 8 10 2019
Statut: ppublish

Résumé

Infections caused by Panton-Valentine leukocidin-positive Staphylococcus aureus (PVL-SA) mostly present as recurrent skin abscesses and furunculosis. However, life-threatening infections (eg, necrotizing pneumonia, necrotizing fasciitis, and osteomyelitis) caused by PVL-SA have also been reported.We assessed the clinical phenotype, frequency, clinical implications (surgery, length of treatment in hospitals/intensive care units, and antibiotic treatments), and potential preventability of severe PVL-SA infections in children.Total, 75 children treated for PVL-SA infections in our in- and outpatient units from 2012 to 2017 were included in this retrospective study.Ten out of 75 children contracted severe infections (PVL-methicillin resistant S aureus n = 4) including necrotizing pneumonia (n = 4), necrotizing fasciitis (n = 2), pyomyositis (n = 2; including 1 patient who also had pneumonia), mastoiditis with cerebellitis (n = 1), preorbital cellulitis (n = 1), and recurrent deep furunculosis in an immunosuppressed patient (n = 1). Specific complications of PVL-SA infections were venous thrombosis (n = 2), sepsis (n = 5), respiratory failure (n = 5), and acute respiratory distress syndrome (n = 3). The median duration of hospital stay was 14 days (range 5-52 days). In 6 out of 10 patients a history suggestive for PVL-SA colonization in the patient or close family members before hospital admission was identified.PVL-SA causes severe to life-threatening infections requiring lengthy treatments in hospital in a substantial percentage of symptomatic PVL-SA colonized children. More than 50% of severe infections might be prevented by prompt testing for PVL-SA in individuals with a history of abscesses or furunculosis, followed by decolonization measures.

Identifiants

pubmed: 31567961
doi: 10.1097/MD.0000000000017185
pii: 00005792-201909200-00031
pmc: PMC6756729
doi:

Substances chimiques

Bacterial Toxins 0
Exotoxins 0
Leukocidins 0
Panton-Valentine leukocidin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e17185

Références

Infect Immun. 2009 May;77(5):2159-67
pubmed: 19237525
BMJ Case Rep. 2011 Jun 29;2011:
pubmed: 22693181
Clin Microbiol Rev. 2015 Jul;28(3):603-61
pubmed: 26016486
Nat Microbiol. 2018 Jun;3(6):708-717
pubmed: 29736038
Int J Antimicrob Agents. 2018 Jan;51(1):16-25
pubmed: 29174420
PLoS One. 2009 Jul 27;4(7):e6387
pubmed: 19633710
J Pediatr Hematol Oncol. 2018 Mar;40(2):e73-e76
pubmed: 29200147
Sci Rep. 2018 Feb 1;8(1):2185
pubmed: 29391581
BMJ. 2011 Sep 09;343:d5479
pubmed: 21908526
Pediatr Infect Dis J. 2017 Dec;36(12):e347-e348
pubmed: 28938255
J Infect Dis. 2008 Oct 15;198(8):1166-70
pubmed: 18729780
Thromb Haemost. 2013 Apr;109(4):684-95
pubmed: 23348831
BMC Infect Dis. 2015 Jan 09;15:10
pubmed: 25572896
PLoS One. 2017 Dec 19;12(12):e0189961
pubmed: 29261764
Pediatr Infect Dis J. 2004 Aug;23(8):701-6
pubmed: 15295218
Science. 2007 Feb 23;315(5815):1130-3
pubmed: 17234914
Clin Microbiol Rev. 2010 Jul;23(3):616-87
pubmed: 20610826
Lancet. 2002 Mar 2;359(9308):753-9
pubmed: 11888586
Pediatr Infect Dis J. 2012 May;31(5):514-8
pubmed: 22327874
BMC Infect Dis. 2018 Aug 6;18(1):371
pubmed: 30081842
PLoS Pathog. 2010 Jan 08;6(1):e1000715
pubmed: 20072612
Lancet Infect Dis. 2013 Jan;13(1):43-54
pubmed: 23103172
J Infect Dis. 2010 May 15;201(10):1589-97
pubmed: 20367458

Auteurs

Pia-Alice Hoppe (PA)

Department of Pediatric Pneumology, Immunology and Intensive Care.

Susanne Holzhauer (S)

Department of Pediatric Hematology and Oncology.

Birgit Lala (B)

Department of Pediatric Radiology.

Christoph Bührer (C)

Department of Neonatology.

Alexander Gratopp (A)

Department of Pediatric Pneumology, Immunology and Intensive Care.

Leif Gunnar Hanitsch (LG)

Department of Medical Immunology.

Daniel Humme (D)

Department of Dermatology, Venerology and Allergy.

Moritz Kieslich (M)

Department of Pediatric Cardiology.

Tilmann Kallinich (T)

Department of Pediatric Pneumology, Immunology and Intensive Care.

Susanne Lau (S)

Department of Pediatric Pneumology, Immunology and Intensive Care.

Rasmus Leistner (R)

Institute of Hygiene and Environmental Medicine.

Michaela Niebank (M)

Department of Infectious Diseases and Respiratory Medicine.

Anna Pokrywka (A)

Department of Dermatology, Venerology and Allergy.

Hannelore Ringe (H)

Department of Pediatric Pneumology, Immunology and Intensive Care.

Anne-Sophie Schaper (AS)

Department of Neonatology.

Jennyver-Tabea Schröder (JT)

Department of Pediatric Surgery, Charité - Universitätsmedizin Berlin.

Carsten Schwarz (C)

Department of Pediatric Pneumology, Immunology and Intensive Care.

Doris Staab (D)

Department of Pediatric Pneumology, Immunology and Intensive Care.

Miriam Songa Stegemann (MS)

Department of Infectious Diseases and Respiratory Medicine.

Stephanie Thee (S)

Department of Pediatric Pneumology, Immunology and Intensive Care.

Verena Varnholt (V)

Department of Pediatric Pneumology, Immunology and Intensive Care.

Horst von Bernuth (H)

Department of Pediatric Pneumology, Immunology and Intensive Care.
Department of Immunology, Labor Berlin Charité-Vivantes GmbH.
Berlin-Brandenburg Center for Regenerative Therapies.

Steffen Weber-Carstens (S)

Department of Anesthesiology and Operative Intensive Care Medicine Campus Mitte and Campus-Virchow Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Anke Wendt (A)

Department of Pediatric Pneumology, Immunology and Intensive Care.

Renate Krüger (R)

Department of Pediatric Pneumology, Immunology and Intensive Care.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH